PT  - JOURNAL ARTICLE
AU  - Jarju, S.
AU  - Senghore, E.
AU  - Brotherton, H.
AU  - Saidykhan, A.
AU  - Jallow, S.
AU  - Krubally, E.
AU  - Sinjanka, E.
AU  - Ndene, M.N.
AU  - Bajo, F.
AU  - Sanyang, M.
AU  - Saidy, B.
AU  - Bah, A
AU  - Forrest, K.
AU  - Clarke, E.
AU  - D’Alessandro, U.
AU  - Usuf, E.
AU  - Cerami, C.
AU  - Roca, A.
AU  - Kampmann, B.
AU  - de Silva, T. I.
TI  - Circulation of respiratory viruses during the COVID-19 pandemic in The Gambia
AID  - 10.1101/2022.08.08.22278521
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.08.08.22278521
4099  - http://medrxiv.org/content/early/2022/08/14/2022.08.08.22278521.short
4100  - http://medrxiv.org/content/early/2022/08/14/2022.08.08.22278521.full
AB  - In many countries, non-pharmaceutical interventions to limit SARS-CoV-2 transmission resulted in significant reductions in other respiratory viruses. However, similar data from Africa are limited. We explored the extent to which viruses such as influenza and rhinovirus co-circulated with SARS-CoV-2 in The Gambia during the COVID-19 pandemic. Between April 2020 and March 2022, respiratory viruses were detected using RT-PCR in nasopharyngeal swabs from 1397 participants with influenza-like illness. Overall virus positivity was 44.2%, with prevalence higher in children <5 years (80%) compared to children aged 5-17 years (53.1%), adults aged 18-50 (39.5%) and >50 years (39.9%), p<0.0001. After SARS-CoV-2 (18.3%), rhinoviruses (10.5%) and influenza viruses (5.5%) were the most prevalent. SARS-CoV-2 positivity was lower in children <5 (4.3%) and 5-17 years (12.7%) than in adults aged 18-50 (19.3%) and >50 years (24.3%), p<0.0001. In contrast, rhinoviruses were most prevalent in children <5 years (28.7%), followed by children aged 5-17 (15.8%), adults aged 18-50 (8.3%) and >50 years (6.3%), p<0.0001. Four SARS-CoV-2 waves occurred, with 36.1%-52.4% SARS-CoV-2 positivity during peak months. Influenza infections were observed in both 2020 and 2021 during the rainy season as expected (peak positivity 16.4%-23.5%). Peaks of rhinovirus were asynchronous to the months when SARS-CoV-2 and influenza peaked.Competing Interest StatementThe authors have declared no competing interest.Funding Statementthe Bill and Melinda Gates Foundation (INV-015823), a Global Challenge Research Fund award from The University of Sheffield, UK, MRCG Vaccines and Immunity core funding (MC_UP_A900/1122), and PaTS trial funding from a UK Research and Innovation grant (MC_PC_19084).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Both studies were approved by the Gambia Government and MRCG joint ethics committee and the Research Ethics Committee at the London School of Hygiene and Tropical Medicine (LSHTM).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript